Vitamin K antagonists (VKAs) have been the standard of care for treatment of
thromboembolic diseases. Target-specific oral anticoagulants (TSOACs) have been …

Background Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation
(AF), which is more prevalent among CKD patients than the general population. AF causes …

Background Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in
treatment guidelines for preventing stroke and systemic embolic events in people with atrial …

The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned
by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and …

Background Warfarin has been the anticoagulant of choice for the prevention of ischaemic
stroke in patients with atrial fibrillation (AF). Novel oral anticoagulants (NOACs) are …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Objectives To examine the characteristics and persistence in patients newly initiated with
oral anticoagulants (OACs) for stroke prevention in non-valvular atrial fibrillation (NVAF) …

Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF)
patients to an increased risk of stroke. This study describes the real-world discontinuation …

Abstract Background Direct oral anticoagulants (DOACs) are indicated for the prevention of
stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no …

Both apixaban and rivaroxaban have been approved for use in acute venous
thromboembolism (VTE). Although indirect comparison through network meta-analyses of …